Human infections with H7N9 flu first emerged in China in March 2013 and since then, China has reported cases of human H7N9 infection to the The World Health Organization (WHO). Human infections with other subgroups of H7 influenza viruses (H7N2, H7N3 and H7N7) have previously been reported in the Netherlands, Italy, Canada, United States of America, Mexico and the United Kingdom.
Although the virus has not shown sustained person-to-person transmission, some evidence points to limited person-to-person transmission in rare circumstances.
Lonza is offering solutions that help to fight challenges with pandemic potential
Lonza is offering solutions that help to fight challenges with pandemic potential, such as the H7N9 virus. Three selected Lonza formulations have been tested and confirmed to show full efficacy against the Influenza A (H7N9) strain: Lonzagard DR- 25aN, Lonzagard R-82 and Lonza Wipes Plus 2.
Influenza viruses are enveloped, lipophilic viruses, which are sensitive to a wide variety of chemical disinfectants. Specifically adapted strains like H7N9 have the potential to cause severe disease on a pandemic scale. However, enveloped viruses can be inactivated by appropriate disinfectants and suitable sanitisation and disinfection procedures will help to prevent infections.
Basic and general hygiene procedures are recommended to reduce infection risk. The World Health Organization recommends hand hygiene procedures such as the thorough washing or use of hand sanitisers, especially before and after food preparation, before eating, after toilet use and after handling animals or animal waste . In addition, using appropriate cleaning and disinfection strategies for surfaces is recommended to help control the spread of the H7N9 virus.
Lonzagard DR-25aN is a high performance disinfectant cleaner concentrate with an outstanding efficacy spectrum. It inactivates H7N9 at a concentration of 0.5 per cent in 5 minutes. Lonzagard DR- 25aN is available in Europe and Middle East and will be supported through Biocidal Product Regulation (BPR ).
Lonzagard R-82 is an EPA-approved, one-step germicidal detergent and deodorant available in North America. It was shown to inactivate H7N9 on hard nonporous surfaces at a 1:256 dilution in 3 minutes.
Lonza Wipes Plus 2 is an EPA-approved wipe formulation that offers a market-leading set of efficacy claims and a wide variety of substrate options. Lonza Wipes Plus 2 are ready-to-use and inactivate H7N9 on hard nonporous surfaces in 4 minutes. Lonza Wipes Plus 2 are available in North America.
Multiple other Lonzagard formulations have been tested against other Influenza A strains and have demonstrated full activity. Customers should visit for information about Lonzagard formulations available in their area.
